# EDGAR Filing Document

**Accession Number:** 0001846623
**File Stem:** 0001683168-23-000432
**Filing Date:** 2023-1
**Character Count:** 7385
**Document Hash:** 34e9f2d0b3fae3d296543971c3eec51a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-23-000432.hdr.sgml**: 20230131

**ACCESSION NUMBER**: 0001683168-23-000432

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230127

**FILED AS OF DATE**: 20230131

**DATE AS OF CHANGE**: 20230131

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Mehalick David
- **CENTRAL INDEX KEY:** 0001846623

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39669
- **FILM NUMBER:** 23570792

**MAIL ADDRESS:**
- **STREET 1:** 5000 TRESSDALE DRIVE
- **CITY:** GIBSONIA
- **STATE:** PA
- **ZIP:** 15044
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Coeptis Therapeutics Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001759186
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 981465952
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 105 BRADFORD ROAD, SUITE 420
- **CITY:** WEXFORD
- **STATE:** PA
- **ZIP:** 15090
- **BUSINESS PHONE:** 724-934-6467

**MAIL ADDRESS:**
- **STREET 1:** 105 BRADFORD ROAD, SUITE 420
- **CITY:** WEXFORD
- **STATE:** PA
- **ZIP:** 15090

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Bull Horn Holdings Corp.
- **DATE OF NAME CHANGE:** 20181115

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Mehalick David<br><sub>(Last) (First) (Middle)</sub><br>105 BRADFORD RD, SUITE 420<br><sub>(Street)</sub><br>WEXFORD, PA 15090<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-01-27 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_CEO and President_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Coeptis Therapeutics Holdings, Inc. [ COEP ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Non-qualified Stock Options (right to buy)<sup>(1)</sup> | 1.60<sup>(5)</sup> | 2023-01-27 |  | A |  | 375000 |  | <sup>(3)</sup> | <sup>(7)</sup> | Common Stock | 375000 | <sup>(5)</sup> | 375000<sup>(9)</sup> | D |  |
| Incentive Stock Options (right to buy)<sup>(2)</sup> | 1.76<sup>(6)</sup> | 2023-01-27 |  | A |  | 250000 |  | <sup>(4)</sup> | <sup>(8)</sup> | Common Stock | 250000 | <sup>(6)</sup> | 250000<sup>(10)</sup> | D |  |

---

### Footnotes:

(1) On January 27, 2023, the reporting person received a grant of 375,000 stock options, as non-qualified options, under the 2022 equity incentive plan.

(2) On January 27, 2023, the reporting person received a grant of 250,000 incentive stock options, under the 2022 equity incentive plan.

(3) Options will vest over 4 years, with the first 25% vesting on 12/31/23, and the balance vesting in equal quarterly installments over the succeeding three years, with the final options vesting on 12/31/26.

(4) Options will vest over 4 years, with the first 25% vesting on 12/31/23, and the balance vesting in equal quarterly installments over the succeeding three years, with the final options vesting on 12/31/26.

(5) The exercise price is the FMV of the shares, which is equal to the Company's stock price on the Nasdaq Global Market on the day of grant.

(6) The exercise price is equal to 110% of the FMV of the shares on the day of grant.

(7) Expiration date is ten years from the day of grant

(8) Expiration date is five years from the day of grant, as the reporting person is a 10% owner and the options are incentive stock options.

(9) Following the exercise of options under both reported transactions, the reporting person will have a total of 625,000 derivative securities beneficially owned.

(10) Following the exercise of options under both reported transactions, the reporting person will have a total of 625,000 derivative securities beneficially owned.

**Signature:** /s/ David Mehalick  
**Date:** 2023-01-31

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**